Clinical Trial Update: Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating FX06 for the prevention of myocardial reperfusion injury has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Myocardial Infarction
• Myocardial Ischemia

Drugs mentioned

• FX06

Snippet

Sponsor: Fibrex Medical Research & Development GmbH | Conditions: Myocardial Ischemia, Coronary Disease | Phase 2 | Status: COMPLETED